solo para uso en investigación
Cat. No.S2485
| Dianas relacionadas | HDAC PARP ATM/ATR DNA-PK WRN DNA/RNA Synthesis PPAR Sirtuin Casein Kinase eIF |
|---|---|
| Otros Topoisomerase Inhibidores | Camptothecin (CPT) Betulinic acid Beta-Lapachone (S)-10-Hydroxycamptothecin Amonafide Voreloxin (SNS-595) hydrochloride Ellagic acid Cu(II)-Elesclomol Hydroxy Camptothecine Rubitecan |
| Líneas celulares | Tipo de ensayo | Concentración | Tiempo de incubación | Formulación | Descripción de la actividad | PMID |
|---|---|---|---|---|---|---|
| L1210 cell | Cytotoxicity assay | 48 h | Cytotoxic potency required to inhibit L1210 cell growth by 50% after cell drug contact for 48 hrs, IC50=4e-05 μM | |||
| HL60 cells | Cytotoxicity assay | 48 h | Cytotoxicity against human HL60 cells after 48 hrs by MTT assay, GI50=0.33 μM | |||
| MDA435/LCC6 cells | Proliferation assay | Antiproliferative activity against MDA435/LCC6 cells by ELISA, IC50=0.35 nM | ||||
| A2780-cell | Growth inhibition assay | Concentration required to inhibit A2780-cell growth by 50%, IC50=0.55 nM | ||||
| G-361 cell | Growth inhibition assay | Cytotoxic potency required to inhibit G-361 cell growth by 50%, IC50=0.65 nM | ||||
| human HL60 cells | Proliferation assay | 72 h | Antiproliferative activity against human HL60 cells after 72 hrs by SRB assay, IC50=2.5 nM | |||
| human K562 cells | Cytotoxicity assay | 5 days | Cytotoxicity against human K562 cells after 5 days by XTT assay, IC50=2.6 nM | |||
| CH1 cell | Cytotoxicity assay | Cytotoxic potency required to inhibit CH1 cell growth by 50%, IC50=2.65 nM | ||||
| MES-SA cells | Proliferation assay | 72 h | Antiproliferative activity against MES-SA cells by MTT assay after 72 hrs, IC50=3 nM | |||
| A549 cells | Function assay | Activity against A549 cancer cell line, IC50=3.1 nM | ||||
| LoVo cells | Cytotoxicity assay | 144 h | Cytotoxicity against human LoVo cancer cell line was determined after 144 hr, IC50=3.3 nM | |||
| P388 cells | Proliferation assay | Antiproliferative activity against P388 cells by ELISA, IC50=4.3 nM | ||||
| human Daudi cells | Proliferation assay | 72 h | Antiproliferative activity against human Daudi cells after 72 hrs by MTT assay, IC50=5 nM | |||
| SKOV-3 cell | Cytotoxicity assay | Cytotoxic potency required to inhibit SKOV-3 cell growth 50%, IC50=5.3 nM | ||||
| OVCAR-3 cell | Function assay | Antitumor activity against human ovarian OVCAR-3 cell lines, IC50=5.8 nM | ||||
| human MES-SA cells | Proliferation assay | 72 h | Antiproliferative activity against human MES-SA cells after 72 hrs by MTT assay, IC50=6 nM | |||
| PC3 cancer cell | Cytotoxicity assay | 144 h | Cytotoxicity against human PC3 cancer cell line was determined after 144 hr, IC50=7 nM | |||
| MXF7 breast cell | Function assay | Antitumor activity against human mammary carcinoma sensitive MXF7 breast cell line, IC50=8.7 nM | ||||
| HT-29 cell | Cytotoxicity assay | 144 h | Cytotoxic potency required to inhibit HT-29 cell growth by 50% after cell drug contact for 144 hrs, IC5=0.01 μM | |||
| HEK293 cells | Cytotoxicity assay | 72 h | Cytotoxicity against HEK293 cells after 72 hrs by MTT assay, IC50=0.01 μM | |||
| MKN45 cells | Cytotoxicity assay | 144 h | Cytotoxicity against human MKN45 cancer cell line was determined after 144 hr, IC50=0.012 μM | |||
| MES-SA cells | Cytotoxicity assay | 72 h | Cytotoxicity against human MES-SA cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay, IC50=0.012 μM | |||
| FM3 cells | Proliferation assay | 72 h | Antiproliferative activity against human FM3 cells after 72 hrs by MTT assay, IC50=0.013 μM | |||
| MCF-7 cells | Growth inhibition assay | Inhibitory activity against human tumor cell line MCF-7 breast adenocarcinoma, IC50=0.02 μM | ||||
| human small-cell lung cancer | Cytotoxicity assay | Cytotoxicity against human small-cell lung cancer (SCLC), IC50=0.02 μM | ||||
| human HCT116 cells | Cytotoxicity assay | 72 h | Cytotoxicity against human HCT116 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay, IC50=0.022 μM | |||
| human HCT116 cells | Proliferation assay | 72 h | Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay, IC50=0.025 μM | |||
| NCI-H460 cells | Cytotoxicity assay | 48 h | Cytotoxicity against human NCI-H460 cells after 48 hrs by resazurin dye assay, EC50=0.03 μM | |||
| CCRF-CEM cells | Cytotoxicity assay | 48 h | Cytotoxicity against human CCRF-CEM cells assessed as cell viability after 48 hrs by celltiter-blue assay, IC50=0.036 μM | |||
| HeLa cells | Proliferation assay | 72 h | Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay, IC50=0.044 μM | |||
| NCI60 cells | Function assay | 48 h | Antitumor activity against human NCI60 cells after 48 hrs by SRB assay, GI50=47.86 nM | |||
| UACC375 cell | Function assay | Antitumor activity against human melanoma UACC375 cell line, IC50=0.048 μM | ||||
| HT1080 cell | Growth inhibition assay | Inhibitory activity against human tumor cell line HT1080, IC50=0.066 μM | ||||
| MES-SA/Dx5 cells | Proliferation assay | 72 h | Antiproliferative activity against human MES-SA/Dx5 cells after 72 hrs by MTT assay, IC50=0.073 μM | |||
| SF268 cells | Proliferation assay | 48 h | Antiproliferative activity against human SF268 cells after 48 hrs, EC50=0.32 μM | |||
| KB/HeLa cells | Proliferation assay | 48 h | Antiproliferative activity against human KB/HeLa cells after 48 hrs, EC50=0.36 μM | |||
| K562 cells | Growth inhibition assay | 72 h | Growth inhibition of human K562 cells after 72 hrs by MTS method, IC50=0.42 μM | |||
| MDA-MB-231 cells | Proliferation assay | 72 h | Antiproliferative activity against human MDA-MB-231 cells by WST-1 method after 72 hrs, IC50=0.96 μM | |||
| SF268 cells | Cytotoxicity assay | 48 h | Cytotoxicity against human SF268 cells after 48 hrs by SRB assay, GI50=0.97 μM | |||
| HCT116 cells | Cytotoxicity assay | Cytotoxicity against human HCT116 cells by MTT assay, IC50=3.96 μM | ||||
| U937 cells | Cytotoxicity assay | Cytotoxicity against human U937 cells by MTT assay, IC50=6.2 μM | ||||
| HepG2 cells | Proliferation assay | 48 h | Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay, IC50=11.05 μM | |||
| Haga clic para ver más datos experimentales de líneas celulares | ||||||
| Peso molecular | 517.4 | Fórmula | C22H29ClN4O6.2HCl |
Almacenamiento (Desde la fecha de recepción) | |
|---|---|---|---|---|---|
| Nº CAS | 70476-82-3 | Descargar SDF | Almacenamiento de soluciones madre |
|
|
| Sinónimos | NSC-301739 2HCl, Mitozantrone 2HCl | Smiles | C1=CC(=C2C(=C1NCCNCCO)C(=O)C3=C(C=CC(=C3C2=O)O)O)NCCNCCO.Cl.Cl | ||
|
In vitro |
DMSO
: 104 mg/mL
(201.0 mM)
Water : 104 mg/mL Ethanol : Insoluble |
|
In vivo |
|||||
Paso 1: Introduzca la información a continuación (Recomendado: Un animal adicional para tener en cuenta la pérdida durante el experimento)
Paso 2: Introduzca la formulación in vivo (Esto es solo la calculadora, no la formulación. Por favor, contáctenos primero si no hay una formulación in vivo en la sección de Solubilidad.)
Resultados del cálculo:
Concentración de trabajo: mg/ml;
Método para preparar el líquido maestro de DMSO: mg fármaco predissuelto en μL DMSO ( Concentración del líquido maestro mg/mL, Por favor, contáctenos primero si la concentración excede la solubilidad del DMSO del lote del fármaco. )
Método para preparar la formulación in vivo: Tomar μL DMSO líquido maestro, luego añadirμL PEG300, mezclar y clarificar, luego añadirμL Tween 80, mezclar y clarificar, luego añadir μL ddH2O, mezclar y clarificar.
Método para preparar la formulación in vivo: Tomar μL DMSO líquido maestro, luego añadir μL Aceite de maíz, mezclar y clarificar.
Nota: 1. Por favor, asegúrese de que el líquido esté claro antes de añadir el siguiente disolvente.
2. Asegúrese de añadir el (los) disolvente(s) en orden. Debe asegurarse de que la solución obtenida, en la adición anterior, sea una solución clara antes de proceder a añadir el siguiente disolvente. Se pueden utilizar métodos físicos como el vórtice, el ultrasonido o el baño de agua caliente para ayudar a la disolución.
| Targets/IC50/Ki |
Topoisomerase II
PKC
(Cell-free assay) 8.5 μM
|
|---|---|
| In vitro |
La Mitoxantrone induce la fragmentación del ADN y la escisión proteolítica de la poli(ADP-ribosa) polimerasa (PARP), un marcador de la activación de las caspasas, en todos los pacientes estudiados, demostrando que el efecto citotóxico de la Mitoxantrone se debe a la inducción de apoptosis. La Mitoxantrone activa NFkappaB y estimula la degradación de IkappaBalpha en la línea celular de leucemia promielocítica HL60 pero no en las células variantes, las células HL60/MX2, que carecen de la isoforma beta de la topoisomerasa II y expresan una isoforma alfa truncada que resulta en una distribución subcelular alterada. La Mitoxantrone inhibe la proliferación de PBMC activadas, linfocitos B o líneas celulares T (TCL) antígeno-específicas estimuladas en células presentadoras de antígeno (APC) de manera dosis-dependiente. La Mitoxantrone induce la apoptosis de PBMC, monocitos y DC a bajas concentraciones, mientras que dosis más altas causan lisis celular. |
| In vivo |
La Mitoxantrone disminuye transitoriamente la tasa de crecimiento de los xenoinjertos HID en ratones, pero no afecta la de los xenoinjertos PAC120. La Mitoxantrone provoca la gravedad de las lesiones cardíacas, la nefropatía y la toxicidad intestinal en ratas espontáneamente hipertensas. La Mitoxantrone y el hierro(III) forman un fuerte complejo 2:1, en el que la Mitoxantrone puede actuar como un ligando tridentado. |
Referencias |
|
| Métodos | Biomarcadores | Imágenes | PMID |
|---|---|---|---|
| Western blot | p-ROS1 / ROS1 / p-STAT3 / STAT3 / p-AKT / AKT / p-ERK / ERK |
|
30108778 |
| Growth inhibition assay | Cell number |
|
24349321 |
(datos de https://clinicaltrials.gov, actualizado el 2024-05-22)
| Número NCT | Reclutamiento | Condiciones | Patrocinador/Colaboradores | Fecha de inicio | Fases |
|---|---|---|---|---|---|
| NCT06156761 | Not yet recruiting | Breast Cancer |
Cancer Institute and Hospital Chinese Academy of Medical Sciences|CSPC Ouyi Pharmaceutical Co. Ltd. |
November 28 2023 | Not Applicable |
| NCT05875428 | Recruiting | Diffuse Large B-Cell Lymphoma |
CSPC ZhongQi Pharmaceutical Technology Co. Ltd. |
July 10 2023 | Phase 2 |
| NCT05496894 | Withdrawn | Relapsing Multiple Sclerosis |
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co. Ltd. |
August 2022 | Phase 2 |
Tel: +1-832-582-8158 Ext:3
Si tiene alguna otra consulta, por favor deje un mensaje.